New RAF blocker tested for tough tumors, but study halted early

NCT ID NCT04249843

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 24 times

Summary

This early-phase study tested a new oral drug, BGB-3245, designed to block a protein called RAF that helps some tumors grow. It involved 109 adults with advanced solid tumors that had a specific BRAF mutation and had stopped responding to other treatments. The main goals were to check the drug's safety and find the right dose, but the study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Blacktown Hospital

    Blacktown, New South Wales, 2148, Australia

  • Cedars Sinai Medical Center

    Beverly Hills, California, 90212, United States

  • MD Anderson

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • One Clinical Research

    Nedlands, Perth, 6009, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 2010, Australia

  • The Kinghorn Cancer Centre, St Vincent Hospital Sydney

    Sydney, New South Wales, 2010, Australia

  • University of Virginia Comprehensive Cancer Centre

    Charlottesville, Virginia, 22903, United States

Conditions

Explore the condition pages connected to this study.